

THE SEARLE COMPANY LIMITED
One IBL Centre, 2nd Floor,
Plot # 1. Block 7 & 8, D.M.C.H.S,
Tipu Sultan Road. Off Shakra-e-Faisal,
Karachi Postal Code-75350
Tel: (92-21) 371 70 200, 371 70 201
Fax: (92-21) 371 70 224, 371 70 225

Karachi-Plant
F-319, S.I.T.E., Karachi
Tel: 32578001 (7 lines)
Fax: (92-21) 32564667

Lahore-Plant
32-Km Multan Road, Lahore
Tel: (92-42) 36169990, 36169992
Fax: (92-42) 35380040

Dated: May 28, 2020

Ref: C/PSX-5.6.1(a).20200528-

**The General Manager
Pakistan Stock Exchange Limited
Stock Exchange Building,
Karachi**

Dear Sir,

SEARLE

Material Information

In accordance with section 96 of the Securities Act, 2015 and clause 5.6.1(a) of the Rule Book of the Pakistan Stock Exchange Limited, we hereby convey the following information.

The Searle Company Limited has successfully entered into an exclusive licensing & marketing agreement with Beximco Pharmaceuticals, Bangladesh. Beximco is the first company in the world who developed and introduced generic of Remdesivir for the treatment of Covid-19. Remdesivir is a direct acting antiviral drug that inhibits viral RNA synthesis. Remdesivir is administered intravenously and is authorized for the treatment of hospitalized patients with severe COVID-19 disease. Remdesivir has been granted emergency use authorization (EUA) by the U.S. Food & drug Administration (FDA) & authorities in Japan to treat hospitalized patients with severe Covid-19.

This partnership will provide an immediate supply of the finished product at an affordable price and will help health care providers of Pakistan to treat their hospitalized Covid-19 patients without any delay. Initially, Searle is planning to import Remdesivir in finished form (ready to use) to meet the country's urgent requirements. Searle is actively taking the matter to the relevant authorities of Pakistan for necessary regulatory approval, Searle is confident that in existing pandemic, the relevant authorities will consider the matter on urgent basis to support the product availability on fastest track. Searle is also planning to donate a sizeable quantity to the Government of Pakistan which is actively fighting against this pandemic.

About Beximco Pharmaceuticals:

Beximco Pharmaceuticals listed on the Alternate investment Market (AIM) of London Stock Exchange. Beximco is a leading exporter of Pharmaceuticals in Bangladesh and it has a geographic footprint in more than 50 countries. Beximco's state of the art manufacturing facilities are certified by global regulatory authorities of USA, Europe, Canada, GCC & Latin America, among others. In August 2016, Beximco become the first Bangladeshi Pharmaceuticals Company to export medicine to the US market following its

5

manufacturing site approval by the U.S.FDA in June 2015. For detail information please visit www.beximcopharma.com

About The Searle Company limited:

The Searle Company Limited was incorporated in Pakistan as a private limited company on October 5, 1965 as subsidiary of G.D. Searle & Co., USA. and was acquired by IBL group in 1993 & listed in Karachi stock exchange. Today Searle is one of the leading Pharmaceutical companies in Pakistan, having seven state of the art manufacturing facilities in Karachi, Lahore & Belgium. Searle represents global Partners in Pakistan like, Grunenthal-Germany, Nestle-Switzerland, Reckitt Benckiser-UK, MSD-USA, Vifor-Switzerland, Bausch+Lomb-USA, Santen-Japan, Mabxiences-Spain, Gador-Argentina, CHR Hansen-Denmark to name a few. According to IQVIA IMS, Searle is ranked 2nd largest Pharmaceutical company of Pakistan in Q1 -2020. Searle already bagged various awards and accolades form prestigious forums & magazines like Forbes, Financial Times Stock exchange UK, MSCI & Asia Money. Searle kept itself actively involved in various CSR activities and continuously support to all leading Hospitals, Thalassemia centers, Dialysis centers, Mental Recovery Homes & Educational Institutions. For detail information please visit www.searlecompany.com

You may please inform the members of the Exchange accordingly.

Yours truly,



Zubair Razzak Palwala
Director & Company Secretary

cc: Executive Director / HOD
Corporate Supervision Department (Company Law Division)
Securities & Exchange Commission of Pakistan
NIC Building, 63 Jinnah Avenue, Blue Area
Islamabad